Preclinical News and Research

RSS

CDI and VivoMedica launch pharmaceutical industry consortium

Cellular Dynamics International (CDI) and VivoMedica plc announce the launch of CARDIOTOX - a pharmaceutical industry consortium to validate a human cell model and analysis system for preclinical cardiotoxicity testing of pharmaceutical candidate compounds.

14 Sep 2009

GENova to file for Prostaganin patents in the US and in Europe

GENova Biotherapeutics Inc. ("GENova") today announced that it is preparing for patent application filings in both the US (at the FDA (U.S. Food and Drug Administration (www.fda.gov) for a 510(k) submission) and in Europe through EMEA (European Medicines Agency) subsequent to expected efficacious and non-toxic pre-clinical results for Prostaganin.

14 Sep 2009

Preclinical study results on using uncultured ADRCs to treat periodontitis reported

Cytori Therapeutics reported results from their preclinical study on the use of uncultured adipose-derived regenerative cells (ADRCs) in the treatment of critical periodontal defects in a rat model. The results suggest that the use of ADRCs may reverse the effects of periodontal disease, evidenced by significantly improved alveolar bone healing and decreased gingival (gum) invasion of the defect. The data were reported today at the 95th Annual Meeting of the American Academy of Periodontology in Boston.

14 Sep 2009

VBI's flu vaccine offers protection against H1N1

Variation Biotechnologies, Inc. (VBI), an emerging leader in the discovery and development of novel vaccines to fight infectious diseases, today reported that the company’s proprietary influenza vaccine triggered a robust immune response and provided protection against the H1N1 strain of influenza.

14 Sep 2009

Clinical data on CXA-101 to be presented at ICAAC

Calixa Therapeutics Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of novel antibiotics for the treatment of antibiotic-resistant infections, will present pre-clinical and clinical data in 20 posters at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) that is being held in San Francisco on September 12 to 15, 2009.

14 Sep 2009

Clinical study results of DAS181 against H1N1 influenza presented

NexBio, Inc. announced today the presentation of two studies of DAS181 activity against H1N1 influenza and NAI-resistant influenza at the 2009 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting on Sunday, September 13, 2009, in San Francisco, CA.

14 Sep 2009

Laquinimod study data reveals its neuroprotective and anti-inflammatory properties

Teva Pharmaceutical Industries Ltd. and Active Biotech today presented data further illuminating the novel, dual mechanism of action (MOA) of investigational oral, once-daily, laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS), conferring neuroprotective and anti-inflammatory properties.

14 Sep 2009

Naproxcinod clinical study results presented at the 2009 World Congress on Osteoarthritis

NicOx S.A. today announced that it has made three scientific presentations at the 2009 World Congress on Osteoarthritis (annual congress of the Osteoarthritis Research Society International - OARSI), which was held from September 10 to 13 in Montreal, Canada.

14 Sep 2009

PTH therapy could prevent osteoarthritis

An existing osteoporosis drug is the first ever found to prevent cartilage loss from osteoarthritis following injury to a joint, and may also regenerate some cartilage that has been lost to osteoarthritis, according to an early study presented today at the annual meeting of the American Society for Bone and Mineral Research in Denver.

14 Sep 2009

Alcon to acquire ESBATech AG

Alcon (NYSE:ACL) announced today that it has entered into a definitive agreement to acquire ESBATech AG, a Swiss biotechnology company. Alcon will pay ESBATech shareholders $150 million in cash at closing, plus contingent payments of up to $439 million based upon the achievement of future research and development milestones that would be expected to create value for Alcon.

14 Sep 2009

Signum Biosciences awarded $1.6 million SBIR Phase II grant

Signum Biosciences, Inc has been awarded a $1.6 million Small Business Innovation Research (SBIR) Phase II grant by the National Institute of Allergy and Infection Diseases (NIAID) to continue the development of its topical STM (Signal Transduction Modulator) anti-inflammatory technology for the treatment of inflammatory skin disease.

11 Sep 2009

Genspera to commence G-202 Phase I trial following FDA approval

GenSpera, Inc. announced today that the Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to begin a Phase I study with its target activated pro-drug, G-202, for the treatment of cancer.

11 Sep 2009

Results from a preclinical study of Variation's influenza vaccine to be presented at ICAAC meeting

Variation Biotechnologies, Inc. (VBI), an emerging leader in the discovery and development of novel vaccines to fight infectious diseases, today announced that it plans to present positive results from a preclinical study of the company’s proprietary influenza vaccine at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), being held at the Moscone Convention Center in San Francisco, California.

11 Sep 2009

Amylin and Biocon collaborate to develop a peptide therapeutic for treating diabetes

Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Biocon, Limited (NSE: BIOCON) announced today that they have entered into an exclusive agreement to jointly develop, commercialize and manufacture a novel peptide therapeutic for the potential treatment of diabetes. Amylin and Biocon will collaborate to develop the therapeutic potential of the compound and share development costs. Research will center on Amylin's "phybrid" technology.

11 Sep 2009

Phase II clinical trial of TAK-700 for treating advanced prostate cancer commences

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary Millennium: The Takeda Oncology Company today announced the initiation of the Phase II portion of a Phase I/II clinical trial of TAK-700 in patients with advanced prostate cancer.

11 Sep 2009

GENova Biotherapeutics to obtain three new drug target patents

GENova Biotherapeutics, Inc., ("GENova"), a biotechnology company that develops novel therapeutic proteins that disrupt the advance of life-threatening diseases, is pleased to announce that it is in the process of acquiring three promising new drug target patents that could generate over a billion dollar in royalty fees in the mid to long term.

11 Sep 2009

Ascent Therapeutics demonstrates Pepducin efficacy

Ascent Therapeutics announced today that the Company has demonstrated efficacy in preclinical models in two Pepducin projects. One of the projects targets CXCR4, a key regulator of stem cell and inflammatory cell homeostasis. A second project has yielded the first potent Pepducin agonists for an undisclosed cardiovascular target.

11 Sep 2009

The first CardioGraft patch with MatrACELL technology implant performed

LifeNet Health, a leading allograft bio-implant company, announces the first implant of a CardioGraft(TM) allograft cardiac patch product with MatrACELL(TM)( )decellularization technology. The surgery was performed at Children's Mercy Hospital in Kansas City, Mo by Gary K. Lofland, MD, FACS, Section Chief, Cardiovascular Surgery at Children's Mercy Hospital in Kansas City, Mo, The Joseph Boon Gregg/Missouri Endowed Chair in Pediatric Cardiac Surgery, Professor of Surgery, UMKC.

10 Sep 2009

Esperance Pharmaceuticals begins human clinical trials of its EP-100 cancer therapeutic candidate

Drug discovery and development company Esperance Pharmaceuticals today announced that it has begun enrollment and dosing of patients in a Phase 1 study of EP-100 in patients with advanced solid tumors. EP-100, the lead candidate from Esperance's Cationic Lytic Peptide (CLYP(TM)) platform technology, is a targeted membrane-disrupting peptide (tMDP) designed to seek and destroy cancer cells that over-express luteinizing hormone releasing hormone (LHRH) receptors on their surfaces.

10 Sep 2009

NIH provides Inviragen second major grant to develop a dengue vaccine

Inviragen has received a $600,000 grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to partially support its continued efforts to develop a safe and effective dengue vaccine. The two-year grant will fund a collaborative effort led by Inviragen and involving scientists at the University of Wisconsin and Division of Vector-Borne Infectious Diseases at the Centers for Disease Control and Prevention (CDC). The supported work will include additional optimization of Inviragen’s vaccine to generate more potent immune responses.

10 Sep 2009